{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:27:14Z","timestamp":1779359234489,"version":"3.51.4"},"reference-count":39,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a type of non\u2010Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed\/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed\/refractory aggressive NHL and 1 focusing on MCL post\u2010bortezomib). The purpose of this report is to provide longer follow\u2010up on the MCL\u2010001 study (follow\u2010ups were 6.8 [NHL\u2010002], 7.6 [NHL\u2010003], and 52.2 [MCL\u2010001] months). The 206 relapsed MCL patients treated with single\u2010agent lenalidomide (25 mg\/day PO, days 1 to 21 every 28\u2010days) had a median age of 67 years (63% \u226565 years), 91% with stage III\/IV disease, and 50% with \u22654 previous treatment regimens. With a median follow\u2010up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]\/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%\u201029.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single\u2010agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed\/refractory MCL, including those previously treated with bortezomib.<\/jats:p>","DOI":"10.1002\/ajh.24854","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T01:48:15Z","timestamp":1499824095000},"source":"Crossref","is-referenced-by-count":21,"title":["Long\u2010term analysis of phase II studies of single\u2010agent lenalidomide in relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier","family":"Luigi Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology Ser\u00e0gnoli, University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"Medical University of Vienna  Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevgi","family":"Kalayoglu Besisik","sequence":"additional","affiliation":[{"name":"Istanbul University Faculty of Medicine Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Laure","family":"Casadebaig Bravo","sequence":"additional","affiliation":[{"name":"Celgene Corporation Boudry Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommy","family":"Fu","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at HUMC Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60605-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8961"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2087-z"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.09.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-521898"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12046"},{"key":"e_1_2_8_12_1","unstructured":"TORISEL (temsirolimus) prescribing information. United Kingdom: Pfizer Limited;2017."},{"key":"e_1_2_8_13_1","volume-title":"VELCADE (Bortezomib) Prescribing Information","year":"2015"},{"key":"e_1_2_8_14_1","volume-title":"VELCADE (Bortezomib) for Injection Prescribing Information","year":"2014"},{"key":"e_1_2_8_15_1","volume-title":"IMBRUVICA (Ibrutinib) Prescribing Information","year":"2016"},{"key":"e_1_2_8_16_1","volume-title":"IMBRUVICA (Ibrutinib) Prescribing Information","year":"2017"},{"key":"e_1_2_8_17_1","volume-title":"REVLIMID (Lenalidomide) Prescribing Information","year":"2017"},{"key":"e_1_2_8_18_1","volume-title":"REVLIMID (Lenalidomide) Prescribing Information","year":"2017"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.046"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.027"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13456"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0871"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2221"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.24854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T03:39:25Z","timestamp":1694921965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/ajh.24854"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24854","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}